Covalent narlaprevir- and boceprevir-derived hybrid inhibitors of SARS-CoV-2 main protease
Citations Over TimeTop 1% of 2022 papers
Abstract
Abstract Emerging SARS-CoV-2 variants continue to threaten the effectiveness of COVID-19 vaccines, and small-molecule antivirals can provide an important therapeutic treatment option. The viral main protease (M pro ) is critical for virus replication and thus is considered an attractive drug target. We performed the design and characterization of three covalent hybrid inhibitors BBH-1, BBH-2 and NBH-2 created by splicing components of hepatitis C protease inhibitors boceprevir and narlaprevir, and known SARS-CoV-1 protease inhibitors. A joint X-ray/neutron structure of the M pro /BBH-1 complex demonstrates that a Cys145 thiolate reaction with the inhibitor’s keto-warhead creates a negatively charged oxyanion. Protonation states of the ionizable residues in the M pro active site adapt to the inhibitor, which appears to be an intrinsic property of M pro . Structural comparisons of the hybrid inhibitors with PF-07321332 reveal unconventional F···O interactions of PF-07321332 with M pro which may explain its more favorable enthalpy of binding. BBH-1, BBH-2 and NBH-2 exhibit comparable antiviral properties in vitro relative to PF-07321332, making them good candidates for further design of improved antivirals.
Related Papers
- → Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients(2012)14 cited
- → Boceprevir and telaprevir: new treatments for chronic hepatitis C(2012)1 cited
- → PIN58 Cost Per Sustained Virological Response of Telaprevir and Boceprevir in the Treatment of Genotype 1 Hepatitis C Patients According to the Previous Treatment Response and the Metavir Groups in Brazil(2012)1 cited
- → Treatment patterns, health care resource utilization and costs in united states patients diagnosed with chronic hepatitis c infection(2014)
- Advance in the development of directly anti-HCV agents: telaprevir and boceprevir(2012)